Skip to main content

Advertisement

SpringerLink
Log in

Intestinal Absorption of HMG-CoA Reductase Inhibitor Pravastatin Mediated by Organic Anion Transporting Polypeptide

  • Research Paper
  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

ABSTRACT

Purpose

The purpose of this study is to clarify the impact of organic anion transporting polypeptide (Oatp) on intestinal absorption of the HMG-CoA reductase inhibitor, pravastatin.

Methods

OATP/Oatp-mediated pravastatin uptake was evaluated with Xenopus oocytes systems. Intestinal permeability was measured by an in situ closed loop method in rats. In vivo pravastatin absorption was kinetically assessed by measuring plasma concentration after oral administration in rats.

Results

Uptake of pravastatin by Oatp1a5, Oatp2b1, OATP1A2, and OATP2B1 cRNA-injected Xenopus oocytes was significantly increased compared with that by water-injected oocytes. Naringin, a potent inhibitor of Oatps and Mdr1, decreased the Oatp1a5-mediated uptake of pravastatin with IC 50 value of 30.4 μM. Rat intestinal permeability of pravastatin was significantly reduced in the presence of 1,000 μM naringin. Similar results were obtained in in vivo absorption studies in rats. Furthermore, no significant change in the permeability was observed in the presence of elacridar, a potent inhibitor of both Mdr1 and Bcrp, though the permeability was significantly decreased in the presence of both elacridar and naringin, suggesting that Mdr1 and Bcrp are not involved in intestinal absorption of pravastatin.

Conclusion

Oatp, but not by Mdr1 or Bcrp, contributes to the intestinal absorption of pravastatin in rats.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

Abbreviations

AUC:

area under the plasma concentration-time curve

BCRP/Bcrp:

breast cancer resistance protein

MDR/Mdr:

multidrug resistance

MRP/Mrp:

multidrug resistance-associated protein

OAT:

organic anion transporter

OATP/Oatp:

organic anion transporting polypeptide

P-gp:

P-glycoprotein

REFERENCES

  1. Stewart RA, Sharples KJ, North FM, Menkes DB, Baker J, Simes J. Long-term assessment of psychological well-being in a randomized placebo-controlled trial of cholesterol reduction with pravastatin. The LIPID Study Investigators. Arch Intern Med. 2000;160:3144–52.

    Article  CAS  PubMed  Google Scholar 

  2. Mukhtar RY, Reid J, Reckless JP. Pitavastatin. Int J Clin Pract. 2005;59:239–52.

    Article  CAS  PubMed  Google Scholar 

  3. Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther. 2006;112:71–105.

    Article  CAS  PubMed  Google Scholar 

  4. Tamai I, Nezu J, Uchino H, Sai Y, Oku A, Shimane M. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun. 2000;273:251–60.

    Article  CAS  PubMed  Google Scholar 

  5. Nakakariya M, Shimada T, Irokawa M, Maeda T, Tamai I. Identification and species similarity of OATP transporters responsible for hepatic uptake of beta-lactam antibiotics. Drug Metab Pharmacokinet. 2008;23:347–55.

    Article  CAS  PubMed  Google Scholar 

  6. Hagenbuch B, Meier PJ. Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch. 2004;447:653–65.

    Article  CAS  PubMed  Google Scholar 

  7. Mikkaichi T, Suzuki T, Tanemoto M, Ito S, Abe T. The organic anion transporter (OATP) family. Drug Metab Pharmacokinet. 2004;19:171–9.

    Article  CAS  PubMed  Google Scholar 

  8. Koga T, Shimada Y, Kuroda M, Tsujita Y, Hasegawa K, Yamazaki M. Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Biochim Biophys Acta. 1990;1045:115–20.

    CAS  PubMed  Google Scholar 

  9. Yamazaki M, Suzuki H, Hanano M, Tokui T, Komai T, Sugiyama Y. Na(+)-independent multispecific anion transporter mediates active transport of pravastatin into rat liver. Am J Physiol. 1993;264:G36–44.

    CAS  PubMed  Google Scholar 

  10. Yamazaki M, Akiyama S, Ni’inuma K, Nishigaki R, Sugiyama Y. Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter. Drug Metab Dispos. 1997;25:1123–9.

    CAS  PubMed  Google Scholar 

  11. Hatanaka T. Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events. Clin Pharmacokinet. 2000;39:397–412.

    Article  CAS  PubMed  Google Scholar 

  12. Komai T, Kawai K, Tokui T, Tokui Y, Kuroiwa C, Shigehara E, et al. Disposition and metabolism of pravastatin sodium in rats, dogs and monkeys. Eur J Drug Metab Pharmacokinet. 1992;17:103–13.

    Article  CAS  PubMed  Google Scholar 

  13. Singhvi SM, Pan HY, Morrison RA, Willard DA. Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. Br J Clin Pharmacol. 1990;29:239–43.

    CAS  PubMed  Google Scholar 

  14. Tamai I, Takanaga H, Maeda H, Ogihara T, Yoneda M, Tsuji A. Proton-cotransport of pravastatin across intestinal brush-border membrane. Pharm Res. 1995;12:1727–32.

    Article  CAS  PubMed  Google Scholar 

  15. Kobayashi D, Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I. Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J Pharmacol Exp Ther. 2003;306:703–8.

    Article  CAS  PubMed  Google Scholar 

  16. Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I. Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther. 2004;308:438–45.

    Article  PubMed  Google Scholar 

  17. Tani T, Gram LK, Arakawa H, Kikuchi A, Chiba M, Ishii Y, et al. Involvement of organic anion transporting polypeptide 1a5 (Oatp1a5) in the intestinal absorption of endothelin receptor antagonist in rats. Pharm Res. 2008;25:1085–91.

    Article  CAS  PubMed  Google Scholar 

  18. Maeda T, Takahashi K, Ohtsu N, Oguma T, Ohnishi T, Atsumi R, et al. Identification of influx transporter for the quinolone antibacterial agent levofloxacin. Mol Pharm. 2007;4:85–94.

    Article  CAS  PubMed  Google Scholar 

  19. Kikuchi A, Nozawa T, Wakasawa T, Maeda T, Tamai I. Transporter-mediated intestinal absorption of fexofenadine in rats. Drug Metab Pharmacokinet. 2006;21:308–14.

    Article  CAS  PubMed  Google Scholar 

  20. Shirasaka Y, Li Y, Shibue Y, Kuraoka E, Spahn-Langguth H, Kato Y, et al. Concentration-dependent effect of naringin on intestinal absorption of beta(1)-adrenoceptor antagonist talinolol mediated by P-glycoprotein and organic anion transporting polypeptide (Oatp). Pharm Res. 2009;26:560–7.

    Article  CAS  PubMed  Google Scholar 

  21. Shirasaka Y, Kuraoka E, Spahn-Langguth H, Nakanishi T, Langguth P, Tamai I. Species difference in the effect of grapefruit juice on intestinal absorption of talinolol between human and rat. J Pharmacol Exp Ther. 2010;332:181–9.

    Article  CAS  PubMed  Google Scholar 

  22. Glaeser H, Bailey DG, Dresser GK, Gregor JC, Schwarz UI, McGrath JS, et al. Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther. 2007;81:362–70.

    Article  CAS  PubMed  Google Scholar 

  23. Shirasaka Y, Kawasaki M, Sakane T, Omatsu H, Moriya Y, Nakamura T, et al. Induction of human P-glycoprotein in Caco-2 cells: Development of a highly sensitive assay system for P-glycoprotein-mediated drug transport. Drug Metab Pharmacokinet. 2006;21:414–23.

    Article  CAS  PubMed  Google Scholar 

  24. Shirasaka Y, Masaoka Y, Kataoka M, Sakuma S, Yamashita S. Scaling of in vitro membrane permeability to predict P-glycoprotein-mediated drug absorption in vivo. Drug Metab Dispos. 2008;36:916–22.

    Article  CAS  PubMed  Google Scholar 

  25. Walters HC, Craddock AL, Fusegawa H, Willingham MC, Dawson PA. Expression, transport properties, and chromosomal location of organic anion transporter subtype 3. Am J Physiol Gastrointest Liver Physiol. 2000;279:G1188–200.

    CAS  PubMed  Google Scholar 

  26. Uno S, Uraki M, Ito A, Shinozaki Y, Yamada A, Kawase A, et al. Changes in mRNA expression of ABC and SLC transporters in liver and intestines of the adjuvant-induced arthritis rat. Biopharm Drug Dispos. 2009;30:49–54.

    Article  CAS  PubMed  Google Scholar 

  27. Cheng X, Maher J, Chen C, Klaassen CD. Tissue distribution and ontogeny of mouse organic anion transporting polypeptides (Oatps). Drug Metab Dispos. 2005;33:1062–73.

    Article  CAS  PubMed  Google Scholar 

  28. Fagerholm U, Lindahl A, Lennernäs H. Regional intestinal permeability in rats of compounds with different physicochemical properties and transport mechanisms. J Pharm Pharmacol. 1997;49:687–90.

    CAS  PubMed  Google Scholar 

  29. Bailey DG, Dresser GK, Leake BF, Kim RB. Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice. Clin Pharmacol Ther. 2007;81:495–502.

    Article  CAS  PubMed  Google Scholar 

  30. Shiau YF, Fernandez P, Jackson MJ, McMonagle S. Mechanisms maintaining a low-pH microclimate in the intestine. Am J Physiol. 1985;248:G608–17.

    CAS  PubMed  Google Scholar 

  31. Sakaeda T, Takara K, Kakumoto M, Ohmoto N, Nakamura T, Iwaki K, et al. Simvastatin and lovastatin, but not pravastatin, interactwith MDR1. J Pharm Pharmacol. 2002;54:419–23.

    Article  CAS  PubMed  Google Scholar 

  32. Wang E, Casciano CN, Clement RP, Johnson WW. HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharm Res. 2001;18:800–6.

    Article  CAS  PubMed  Google Scholar 

  33. Yamazaki M, Tokui T, Ishigami M, Sugiyama Y. Tissue-selective uptake of pravastatin in rats: contribution of a specific carrier-mediated uptake system. Biopharm Drug Dispos. 1996;17:775–89.

    Article  CAS  PubMed  Google Scholar 

  34. Hasegawa M, Kusuhara H, Sugiyama D, Ito K, Ueda S, Endou H, et al. Functional involvement of rat organic anion transporter 3 (rOat3; Slc22a8) in the renal uptake of organic anions. J Pharmacol Exp Ther. 2002;300:746–53.

    Article  CAS  PubMed  Google Scholar 

  35. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, et al. Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem. 1999;274:13675–80.

    Article  CAS  PubMed  Google Scholar 

  36. Yamazaki M, Kobayashi K, Sugiyama Y. Primary active transport of pravastatin across the liver canalicular membrane in normal and mutant Eisai hyperbilirubinaemic rats. Biopharm Drug Dispos. 1996;17:645–59.

    Article  CAS  PubMed  Google Scholar 

  37. Dahan A, Amidon GL. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009;297:G371–7.

    Article  CAS  PubMed  Google Scholar 

  38. Ungell AL, Nylander S, Bergstrand S, Sjöberg A, Lennernäs H. Membrane transport of drugs in different regions of the intestinal tract of the rat. J Pharm Sci. 1998;87:360–6.

    Article  CAS  PubMed  Google Scholar 

  39. Lennernäs H. Human intestinal permeability. J Pharm Sci. 1998;87:403–10.

    Article  PubMed  Google Scholar 

  40. Salphati L, Childers K, Pan L, Tsutsui K, Takahashi L. Evaluation of a single-pass intestinal-perfusion method in rat for the prediction of absorption in man. J Pharm Pharmacol. 2001;53:1007–13.

    Article  CAS  PubMed  Google Scholar 

  41. Satoh H, Yamashita F, Tsujimoto M, Murakami H, Koyabu N, Ohtani H, et al. Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos. 2005;33:518–23.

    Article  CAS  PubMed  Google Scholar 

  42. Fukazawa I, Uchida N, Uchida E, Yasuhara H. Effects of grapefruit juice on pharmacokinetics of atorvastatin and pravastatin in Japanese. Br J Clin Pharmacol. 2004;57:448–55.

    Article  CAS  PubMed  Google Scholar 

Download references

ACKNOWLEDGEMENTS

This work was supported in part by a Grant-in-Aid for Scientific Research from Japan Society for the Promotion of Science (JSPS) (Research Project Number: 21790147).

Author information

Authors and Affiliations

  1. Faculty of Pharmacy, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University, Kakuma-machi, Kanazawa, 920-1192, Japan

    Yoshiyuki Shirasaka, Kensuke Suzuki, Takeo Nakanishi & Ikumi Tamai

Authors
  1. Yoshiyuki Shirasaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kensuke Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takeo Nakanishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ikumi Tamai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ikumi Tamai.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shirasaka, Y., Suzuki, K., Nakanishi, T. et al. Intestinal Absorption of HMG-CoA Reductase Inhibitor Pravastatin Mediated by Organic Anion Transporting Polypeptide. Pharm Res 27, 2141–2149 (2010). https://doi.org/10.1007/s11095-010-0216-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11095-010-0216-5

KEY WORDS

Search

Navigation